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Abstract 
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in 
modeled claims for cost-effectiveness and associated recommendations for pricing and access by the Institute for Clinical and Economic 
Review (ICER). The principal objection to ICER reports has been that their modeled claims fail the standards of normal science: they are 
best seen as pseudoscience. The purpose of this latest commentary is to provide a critique of the recently released ICER 2020 Value 
Assessment Framework (VAF). Although ICER has taken upon itself the pole position in health technology assessments and 
recommendations for product pricing in the US health care system, the incremental, lifetime cost-per-QALY modeling methodology 
should not be taken seriously. The creation of imaginary modeled worlds, built entirely from assumption, fails the demarcation test 
between science and pseudoscience. The ICER evidence reports are best seen as the health technology assessment equivalent of 
‘intelligent design’ in counterpoint to ‘natural selection’. It is surprising, therefore, that health care decision makers should take ICER’s 
recommendations seriously as providing ‘approximate information’ for formulary decision making. What is not appreciated is that the 
claims made by ICER lack credibility, are impossible to evaluate and lack the ability to be replicated across treatment settings. Indeed, 
the models presented under the guise of a ‘state of the art’ value assessment were never intended to support evaluable claims. We 
have no idea and will never know if they are right or if they are wrong. ICER’s position becomes even more untenable once the  models 
presented are assessed in detail. Without in any way supporting the ICER methodology, it is worth noting that all too often ICER’s claims 
for incremental QALYs in specific models are based upon what appears to be, from the limited evidence presented, a casual and ad hoc 
assemblage of utility scores from diverse constructs. This is a critical weakness given the role attributed by ICER to the modeled cost-
per-QALY claims as central to ICERs imaginary value assessment. ICER also overlooks the fact that the utility scores it captures from the 
literature to populate its imaginary reference case world lack objectivity. They are ordinal rather than interval measures. To apply these 
manifest scores to time spent in a disease stage and then aggregate these over different disease stages is nonsensical. The critical issue 
is one of instrument development. The case made here is for the application of Rasch Measurement Theory (RMT) to construct a 
unidimensional instrument with interval properties, in this case from the needs fulfillment construct of quality of life (QoL). Unless an 
instrument meets RMT standards in its development, the logic of Rasch modeling to achieve fundamental measurement standards 
means that other scales are, by definition, ordinal. It is absurd to ‘assume’ they are interval. RMT is designed to create instruments to 
evaluate change and test hypotheses. In the absence of instruments that have RMT properties, the cost-per-QALY reference case 
modelling meme collapses. It is an analytical dead end. If we are to support a meaningful scientific program to discover new facts to 
support health care delivery and improve the lives of patients, caregivers and their families, then ICER should be put to one side. 
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Introduction 
The release of the 2020 version of the Institute for Clinical and 
Economic Review’s (ICER) Value Assessment Framework (VAF)      
represents a millstone in health technology assessment 1. It 
affirms ICER’s ongoing commitment to the construction of 
imaginary worlds to support pricing and access 
recommendations. ICER sees its VAF as forming the backbone 
of rigorous evidence reports that, within a broader mechanism 
of stakeholder and public engagement, will help the United 
States evolve towards a health system that provides fair pricing, 
fair access, and a sustainable platform for future innovation.  
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While this no doubt laudatory objective must appeal to a wide 
audience, it is a backbone that fails the standards of normal 
science. To claim that ICER presents rigorous evidence is 
patently absurd when their modeled claims are deconstructed. 
While ICER sees its VAF as seeking to place scientific methods 
and evidence analysis at the heart of a clearer and more 
transparent process, the fact is that the modeled claims that 
drive recommendations for pricing (‘fair prices’) and access 
(‘fair access’) are imaginary and are the antithesis of ‘scientific 
methods’. The ICER model is only one of a potential multiverse 
of competing imaginary worlds all with their own meaningless 
recommendations. The reference case model, as demonstrated 
in this commentary is not a ‘sustainable platform’; it is an 
unnecessary distraction. More to the point: the so-called 
population perspective rests on generic utilities that fail the 
axioms of fundamental evidence; they are an ordinal manifest 
score which means that building quality adjusted life year 
(QALY) claims based on ordinal ‘values’ is nonsensical.  
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                        2020, Vol. 11, No. 1, Article 12                        INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v11i1.2444 
2 
 
Previous commentaries in INNOVATIONS in Pharmacy have, 
over the past 4 years, both reviewed ICER evidence reports as 
well as providing detailed critiques of the ICER methodology: in 
particular the failure of the application of the ICER reference 
case 2 to meet the standards of normal science 3 4 5 6 7 8 9 10 11. 
The argument is straightforward. The ICER modeled reference 
case technology assessment fails the demarcation test and is 
best seen as pseudoscience (intelligent design) rather than 
normal science (natural selection). The lifetime reference case 
requirements fail to generate credible claims. By definition, the 
claims are not evaluable and, by extension, not replicable 
across treating populations. We have no idea if the claims are 
right or if they are wrong, we will never know and were never 
intended to know.  
 
Certainly, the reference case methodology is seen as the ‘state 
of the art’ in health technology assessment which supports the 
construction of imaginary, simulated models projecting over 
the lifetime of a hypothetical patient cohort to generate 
incremental cost-per-QALY claims based on ordinal utilities. 
These claims are set against willingness to pay thresholds to 
convince an audience, who are typically non-technical, to take 
at face value recommendations for product pricing and access 
based on a hypothetical world.  It is acknowledged by 
technology assessment groups that these are artificial (yet 
‘realistic’) but that their redeeming feature, apparently, is that 
they generate ‘approximate information’ for decision makers; 
or, more precisely, ‘imaginary’ information (or disinformation) 
12. It is, perhaps, surprising, if not of concern, that a major focus 
of health economics is on the fabrication of imaginary worlds 
with a disregard of the axioms of fundamental measurement. 
 
Even if attempts were made by a successor to ICER to use the 
reference case framework to create credible and evaluable 
claims, the result would still fail the demarcation test. This is 
because, apart from the lifetime perspective, the QALY 
construct fails to meet the required axioms of fundamental 
measurement. Generic utility ‘values’ and the majority of 
disease specific patient reported outcomes (PRO)  instruments 
fail to meet, as detailed below, the fundamental measurement 
axioms of invariance of comparisons and sufficiency; the 
unidimensional properties of the Rasch model 13 14.  If health 
technology assessment has any hope of being taken seriously 
then it needs to generate claims that are disease specific, 
credible, evaluable and falsifiable; claims that are based on a 
coherent quality of life construct (QoL) and meet the standards, 
notably construct validity and order, for Rasch Measurement 
Theory (RMT) in instrument development. This has been 
recognized in papers presented in both the ISPOR house journal 
Value in Health (in 2004) 15 16 17 and more recently in the Journal 
of Medical Economics (2019) 18 19. 
 
The purpose of this commentary is to review the 2020 Value 
Assessment Framework (VAF) which ICER proposes to use in 
future imaginary evidence reports and recommendations for 
pricing and affordability. The focus of this critique is to make 
the case that that ICER’s VAF should not be taken seriously. Its 
modeled claims for value claims not only strain credulity, but 
judged against the standards of normal science are nonsensical. 
 
While the ICER approach embraces the health technology 
assessment meme advanced by the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) and a 
number of single payer health system assessment agencies 
such as the National Institute for Health and Care Excellence 
(NICE) in the UK, the meme fails standards for fundamental 
measurement, discovery and the growth of knowledge that 
have been place for almost the past 400 years.  
 
The manifest shortcomings in the ICER reference case modeling 
are considered from a number of perspectives: 
 
 The construction, by assumption, of an imaginary world 
that is intended, not to test hypotheses, but to generate 
‘approximate information’ 
 A failure to point out that the ICER reference case can 
produce a multiverse of competing imaginary world all 
of which may have, or can be constructed to have,  
competing recommendations 
 A focus on generic ordinal utility measures of ‘benefit’ 
that argue for ‘measuring’ health related quality of life 
(HRQoL) but which fail to provide a coherent patient-
centric latent quality of life construct; as well as failing 
to meet the required standards  of Rasch measurement 
theory (RMT) for instrument development  
 Building a VAF around ordinal utility ‘fabricated’ QALYs 
which lack any meaningful interpretation in terms of 
the fundamental axioms of measurement theory 
 Selecting an ordinal utility measure (e.g., EQ-5D-3L) to 
generate QALYs which is only one of a number of 
competing ordinal generic measures all of which fail to 
meet fundamental measurement axioms  
 Putting to one side the ‘voice of the patient’ in ignoring 
value claims that are a direct measure of needs 
fulfillment  
 
Building Instructions for Fabricating Imaginary Worlds 
The 2020 VAF is quite clear: ICER is committed to its reference 
case to create imaginary assumption-driven lifetime models to 
track a hypothetical cohort of patients assumed to be treated 
with and responding to specific therapies. The objective of the 
economic evaluation is to determine the incremental cost-
effectiveness of the cost per unit of health benefit gained of one 
treatment over another. The response to therapy, measured as 
imaginary QALYs, is a community preference weighted 
response. The building kit instructions to support any number 
of imaginary worlds are detailed in the reference case 2. With 
few exceptions, the deterministic base case reference case is 
applied uniformly across all products and devices assessed by 
ICER. Evidence reports are presented and reviewed. Competing 
model structures are not considered. 
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The common outcome measure, to support value claims and 
ICER recommendations, is the imaginary modeled incremental 
cost-per-QALY for a hypothetical patient population. This is, by 
assumption, a lifetime or course of chronic disease QALY 
framework; extending 10, 20 or 30 years into the unknown but 
modeled ICER-assumed future. The choice of utility metric, 
derived from a literature review, is a US preference based multi-
attribute system. A specific measure (e.g., EQ-5D-5L) is not 
mandated although ICER’s preference is apparently for the EQ-
5D-3L. The imaginary lifetime incremental cost-per-QALY 
constructed measure is matched against willingness-to-pay 
thresholds ($50,000 to $200,000 per QALY) and 
recommendations made for possible price discounting together 
with budget impact assessments. 
 
It is quite clear that there is no intention that the reference case 
modeled claims being presented should be in a form that allows 
empirical evaluation. Indeed, the structure of the reference 
case and its lifetime perspective means that any claims are 
impossible to evaluate empirically and were never intended to 
be evaluable. ICER defends its imaginary construct and claims 
in terms of validation against other imaginary worlds, the 
internal consistency of the model structure, discussions with 
the model builders and the choice of its assumptions. While this 
may seem an odd way to establish an ‘imaginary’ value, it is 
important to remember that this is in the realm of science 
fiction; adventures in imaginary VAF worlds. As detailed below, 
the failure to recognize that the utility measure fails to meet 
the standards of Rasch Measurement Theory (RMT) means that 
the ordinal lifetime QALY claims have no merit anyway.  
 
Certainly, the ICER imaginary world model is hedged with mini-
modeled scenarios to capture the effect of modifying imaginary 
assumptions, structural parameter assumptions and the 
application of sensitivity analyses. This does not change the fact 
that the model is an entirely imaginary construct which, as 
detailed below, fails the demarcation test, between science and 
pseudoscience. It is only one of a potential multiverse of 
imaginary constructs that may be applied to the specific disease 
area and therapies under review. There is no hint in the ICER 
guidelines for constructing imaginary world that empirical 
assessment might be considered or that any prospective 
audience member would be remotely interested in evaluable 
incremental cost-effectiveness claims.  
 
ICER is not NICE 
It is not clear where ICER’s belief in its mandate both to perform 
as sole arbiter for health technology assessment in the US 
originates and to provide ‘much needed’ cost-per-QALY inputs 
to better manage resource allocation in health systems 
originates. There does not seem to have been a groundswell of 
opinion where US health system decision makers have 
approached ICER, pleading for mandated incremental cost-per-
QALY modeled claims based on generic multi-attribute 
preference systems, as the national formulary decision criteria. 
Certainly the Academy of Managed Care Pharmacy (AMCP) has 
embraced the imaginary world meme in its formulary 
submission guidelines, but we also find instances of 
professional groups proposing alternative value metrics to 
support formulary decisions and guideline development 20.  
 
Perhaps most importantly, there is scant evidence to show that 
health systems have the staff and the skills necessary to assess 
the merits, if any, of imaginary constructs or take these on 
board as a management tool. If it takes an 8 month gestation 
period for ICER to come to term in its clinical assessment of 
target therapies and its construction of imaginary cost-per-
QALY worlds, it is difficult to see a comparable deconstructive 
effort from health systems. After all, if they take the view that 
the effort would be in pursuit of a pseudoscientific construct, 
the most reasonable response would be to put it to one side. 
Unfortunately, rather than deconstructing the imaginary ICER 
claims and recognizing their lack of scientific merits, insurers 
and health systems take them at face value.  
 
ICER is in a quite different position from that of the National 
Institute for Health and Care Excellence (NICE) in the UK 21. 
While ICER may be seen as a simulacrum of NICE (NICE-lite), the 
facts are that (i) it is not operating in a single payer health care 
system and (ii) it has no legislative role to provide guidance on 
the acceptance of technologies as NICE does within the English 
National Health Service (NHS). ICER’s perceived and self-
appointed role as the arbiter of value judgements for the US 
health market, supported by proclaimed processes of 
stakeholder involvement, clinical benefit assessment, model 
building and, ultimately, voting by an ICER appointed expert 
panel on the merits or otherwise of target therapies, should not 
obscure the fact that the end-results are imaginary value 
judgements.  
 
NICE takes a reference case approach to establish model 
parameters, to generate incremental cost-per-QALY claims and 
apply willingness to pay thresholds. In this case, however, 
rather than an in-house model developed by its staff, 
manufacturers are asked by NICE to submit their own reference 
case model. This is typically a lifetime incremental imaginary 
cost-per-QALY model with the EQ-5D-3L generic HRQoL 
instrument as the standard utility measure. The point is that 
with NICE and other countries such as  Canada (CADTH) 
Australia (PBAC), New Zealand (PHARMAC) and Ireland (HIQA) 
who have followed NICE’s lead in mandating the construction 
of simulated or modeled worlds to support formulary 
submissions, the requirement has legislative and regulatory 
backing 22 23 24 25. Lifetime imaginary ‘for approximate 
information’ worlds are the required standard. While modeling 
reference case lifetime value judgements might seem odd and 
be objected to on grounds of scientific merit, there is an 
acceptance of this approach. As noted in a recent commentary: 
The playing field is level and all parties know the rules of the 
‘game’. There are even imaginary world referees, typically in 
academic institutions, who will adjudicate the manufacturer’s 
imaginary submission. They can pronounce whether it is 
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acceptable, modifiable or should be replaced by the referees 
own proposal for an imaginary world. NICE, as senior referee, is 
the judge 26 . 
 
There is no reason why ICER should assume that value 
judgements based on constructed evidence from simulated 
worlds should have relevance to health care decision making in 
the US. The US is not a single payer health system. There is no 
legislated or regulatory across-the-board requirement for 
imaginary reference case modeling to support value 
judgements and formulary decisions. Certainly, ICER might 
believe in the sure and certain hope that incremental cost-per-
QALY lifetime simulation models are the current and future  
‘state of the art’ in health technology assessment, a position 
taken by professional groups such as ISPOR. This does not mean 
that the ICER business model standard is appropriate.  Indeed, 
under the Affordable Care and Patient Protection Act (2010) it 
is made clear that the Patient Centered Outcomes Research 
Group (PCORI) should exclude discounted cost-per QALY or 
similar measures as threshold values for priority setting in 
health by the Centers for Medicare & Medicaid Services (CMS) 
27. While this exclusion may give pause to those advocating a 
role for imaginary QALYs in pricing and access, the debate 
overlooks a more substantive concern: the ICER business model 
lacks scientific merit. It is best seen, as detailed below, as 
pseudoscience. 
 
Similar objections apply to the recent proposals by ICER for the 
modeled value assessments of transformative therapies (SSTs) 
28 29. These have been reviewed in a recent commentary in 
INNOVATIONS in Pharmacy 30. The proposed framework for 
SSTs will continue to use the reference case to construct 
imaginary worlds, subsumed within the overall VHF 
methodology, As such, they should be rejected.  
 
Meeting the Standards of Normal Science 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for products and devices 
is unexceptional. Since the 17th century, it has been accepted 
that if a research agenda is to advance, if there is to be an 
accretion of knowledge, there has to be a process of discovering 
new facts. Indeed, as early as the 16th century Leonardo da Vinci 
(1452 – 1519) in notes that appeared posthumously in 1540 for 
his Treatise on Painting (published in 1641) clearly anticipated 
the standards for the scientific method which were widely 
embraced a century later in rejecting thought experiments that 
fail the test of experience. By the 1660s, the scientific method, 
following the seminal contributions of Bacon, Galileo, Huygens 
and Boyle, had been clearly articulated by associations such as 
the Academia del Cimento in Florence (1657) and the Royal 
Society in England (founded 1660; Royal Charter 1662) with 
their respective mottos Provando e Riprovando (prove and 
again prove) and nullius in verba (take no man’s word for it) 31.   
 
By the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper (Sir Karl 
Popper 1902-1994) in his advocacy of a process of ‘conjecture 
and refutation 32 33 .  Hypotheses or claims must be capable of 
falsification; indeed they should be framed in such a way that 
makes falsification likely. Life becomes more interesting if claims 
are falsified because this forces us to reconsider our models and 
the assumptions built into those models. This leads to the 
obvious point that claims or models should not be judged on the 
realism or reasonableness of assumptions or on whether the 
model ‘represents’ for a public advocacy research group such as 
ICER their belief in lifetime comparative cost-per-QALY 
outcomes future fictional reality. A future reality that is unknown 
and unknowable, and is never intended to be known. This is an 
intellectual and analytical dead-end. 
Although Popper’s view on what demarcates science (e.g., 
natural selection) from pseudoscience (e.g., intelligent design) is 
now seen as an oversimplification involving more than just the 
criteria of falsification, the demarcation criteria remains 34.  
Certainly, there are different ways of doing science but what all 
scientific inquiry has in common is the ‘construction of 
empirically verifiable theories and hypotheses’. Empirical 
testability is the ‘one major characteristic distinguishing science 
from pseudoscience’; theories must be tested against data. 
Indeed, paradoxically, while the development of pharmaceutical 
products and the evidence standards required by the Food and 
Drug Administration (FDA) for product evaluation and marketing 
approval are driven by adherence to the scientific method, once 
a product is launched and claims made for cost-effectiveness 
and, in the case of ICER, modeled for pricing and access 
recommendations, the scientific method is put to one side. 
Pseudoscience succeeds science. Darwin’s (Charles Darwin 1809 
-1882) on The Origin of Species 35 is succeeded by Of Pandas and 
People 36. 
The rejection of a research program that meets the standards of 
normal science by groups such as ICER is best exemplified by the 
latest version of the Canadian health technology guidelines 
where it is stated: Economic evaluations are designed to inform 
decisions. As such they are distinct from conventional research 
activities, which are designed to test hypotheses 37. While this 
position puts modeled health technology assessment in the 
category of pseudoscience, it is also what may be described as a 
relativist position. Rather than subscribing to the position that 
the standards of normal science are the only standards to apply 
in health care decisions and value claims, the relativist believes 
that all perspectives are equally valid. Health care decisions are 
to be understood sociologically. No one body of evidence is 
superior to another. Results of a lifetime modeled simulation are 
on an equal basis with those of a pivotal Phase 3 randomized 
clinical trial. For the relativist, the success of a scientific research 
program, in this case one built on hypothetical models and 
assumptions, rests not on its ability to generate new knowledge 
but on its ability to mobilize the support of the community.  
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Basing decisions on models and simulations underpins the 
consensus view that evidence is constructed, never discovered. 
Instead of coming to grips with reality, science is from their 
perspective about rhetoric, persuasion and authority 31. Truth is 
consensus. 
 
The Health Technology Assessment Meme 
If truth is consensus, how is this consensus, resting upon the 
construction of imaginary worlds, maintained; in this case for 
over 30 years of imaginary cost-effectiveness modeled claims. 
The ISPOR consensus, embraced by ICER, on health technology 
assessment has been characterized in previous commentaries as 
a meme. This is deliberate, as it underpins the interpretation of 
ICER’s continued unqualified acceptance of the reference case as 
its core business model, as a sociological phenomenon.  
 
After all, it is unusual to find the central pillar in an academically 
respectable social science the construction of fictional imaginary 
worlds; in this case to support non-evaluable cost-outcomes 
claims with the fabrication of ‘approximate information’. In this 
context, the ISPOR/ICER cost-per-QALY reference case can be 
characterized as a unit of cultural transmission or unit of 
imitation; as an analog of gene pool propagation ‘by leaping from 
body to body via sperm or  eggs’ 38.  
 
One of the key health technology assessment meme tenets is 
the belief in the QALY. A venerated dogma which is central to 
value assessment. Human beings are good at imitation. The 
reference case meme, the faith in the QALY, appears to be 
adept in its infectivity, supported by an organizational 
infrastructure to defend it against competition in the 
technology assessment meme pool, ensuring survival through 
supporting propagation, longevity, fecundity (or acceptability) 
and, of particular note high copying fidelity. The control 
exercised over the meme ensures few mutations. As Dawkins 
notes, few individuals brought up in a certain faith switch to 
other faiths or reject the ‘faith and mysteries’ of their parent’s 
belief system 39.  The widespread adoption and propagation of 
this meme in seen with literally thousands of imaginary world 
technology assessments published over the past 30 plus years. 
Add to this continued willingness of journal editors to publish 
imaginary claims, even if they are sponsored marketing 
exercises. In the case of this continued acceptance it is 
sufficient to point to the advocacy of the meme by 
organizations such as ISPOR with its global membership, its 
good practice guidelines for constructing imaginary worlds, 
training programs for newly arrived imaginary world 
apprentices, and conferences, together with endorsements 
from technology assessment agencies such as NICE, CADTH and 
the PBAC. Add to this its place in university post-graduate 
programs (including Colleges of Pharmacy) together with the 
contribution of textbooks that have rigorously supported the 
creation of imaginary worlds 40.  
 
It is of interest to speculate, given the receptive audience for 
imaginary technology assessment claims, together with the 
‘technical’ belief structure that underpins them (e.g., 
probability sensitivity analysis), whether or not we are 
receptive to pseudoscientific claims; is there a response bias 
toward accepting pseudoscientific claims as true? Is there an 
asymmetry between belief and unbelief?  Is additional 
processing required if this bias is to be overcome? Is there an 
asymmetry that reinforces acceptance of the technology 
assessment meme and the acceptance of ‘imaginary 
approximate information’ even though it is a ‘mystery’ as to 
what this actually means? Perhaps we just accept it on ‘faith’? 
 
A further possibility is our inability to detect pseudoscientific 
constructs. Do we judge something as profound because we 
have failed to understand it?  Are there measurable differences 
in the ability of individuals to discern or detect pseudoscientific 
statements including the more complex (and often obscure) 
modeling constructs supporting ICER imaginary worlds and 
attendant scenarios?  Can we engage in analytic thinking? Do 
we understand the axioms of fundamental measurement? To 
what extent is our ability to reflect on, rather than reflexively 
accept at face value, offset by our acceptance of a belief system 
that is central to our professional standing?  
 
Perhaps we should not be surprised that the nature of the 
scientific method is not appreciated. After all, some 27% of 
Americans don’t accept heliocentrism, 48% don’t accept 
common ancestry (natural selection) and 61% don’t accept the 
big bang 41 . Even so, we should not be unduly pessimistic as a 
recent survey indicated that probably less than 2% of Americans 
believe in a flat earth, although globally traveling flat-earthers 
seem active on the conference front.42. There are, of course 
those who require visual evidence. One respondent remarked 
that he did not believe in gravity because he could not see it. 
Presumably he did not believe in imaginary worlds either. 
 
Approximate Information 
Central to the ICER business model is the need to express value 
judgements on constructed estimates of lifetime incremental 
costs-per-QALY.  This is an article of faith for those supporting 
the health technology assessment meme. As stated by Neuman 
et al in the 2018 ISPOR Task Force Report on health economics 
in value assessment: Leaders in the field of economic evaluation 
in health care have long recommended that analysts seeking to 
inform resource allocation decisions approximate the value of 
interventions in terms of incremental cost-per-QALY gained 
(emphases added) 43.  It is not clear, in constructing imaginary 
worlds, how we are to distinguish the ‘approximate’ from the 
‘non-approximate’ information content and how this 
‘approximate information’ factors into formulary decisions.  
 
If we accept the primacy of the scientific method, as a tool for 
discovery, over the recycling of ‘evidence based’ assumptions to 
create imaginary modeled claims, then any defense of the 
reference case as fabricating ‘approximate information’ to 
‘support’ formulary decisions, pricing and access, seems odd. 
After all, we could equally well talk about ‘approximate 
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disinformation’. When does ‘approximate information’ mutate 
to ‘approximate disinformation’? Presumably, the role of 
academic referee centers for imaginary worlds is to render 
judgement for a Jesuitical ‘housekeeping seal of approval’ on the 
‘chosen’ imaginary world. After some 338 years Galileo would, 
no doubt, appreciate the irony (Galileo Galilei 1564-1642). 
Although the criteria are not entirely obvious, the preference 
would be presumably for one set of assumptions to drive a 
hypothetical world 30 years into the future, with imaginary value 
claims that are ’nearly precise or correct’ when matched to an 
imaginary (yet unknowable) lifetime claim. Crystal ball or tea 
leaves? 
 
Models and Assumptions 
It is accepted that knowledge is provisional and permanently 
so. This stems from the obvious point that we can at no stage 
prove that what we ‘know’ is true. Attempting to believe or 
justify our belief in a theory is logically impossible. What we can 
do, by empirical assessment, is to try and demonstrate our 
preference for one theory over another (and apply it to the best 
of our knowledge) 32.  
 
Constructing imaginary worlds which were never intended to 
generate potentially falsifiable claims cannot, therefore, be 
defended by an appeal to the ‘truth’ of their assumptions. If a 
health technology assessment claim is built upon a series of 
assumptions, a reasonable question is to ask what is the status 
of the various assumptions? Are they to be viewed as 
‘reasonable’ or ‘realistic’ metrics for an unknown future reality? 
Can we just assume that utilities have interval scale properties? 
Have the utilities been selected from the literature because 
they seem appropriate? Are they the ‘best available’ from 
limited data? Are they all that are available? 
 
More to the point, there is a belief in the fact that when the 
selected assumptions are based, where feasible, on an 
empirical study, this validates the choice of assumption.  If the 
model is intended to incorporate utilities that have been 
reported in one or two studies (usually as few as that) for 
progression and time spent in the stages of a disease over a 
hypothetical future lifetime, then there is an immediate 
methodological issue. To claim that an assumption is valid is to 
revisit Hume’s induction problem (David Hume 1711-1776): an 
appeal to facts to support a scientific statement. Unfortunately, 
as Hume pointed out, no number of singular observations can 
logically entail an unrestricted general statement. Certainly, 
there may be comfort in reporting that ‘so far’ the claim that all 
swans are white has not been contradicted (until that Qantas 
vacation in Western Australia) so that one fully expects the next 
swan to be white. But as Hume pointed out, this is a fact of 
psychology and does not entail any general statement. From a 
utility perspective, the fact that one hundred papers have 
agreed (within limited bounds) generic ordinal utilities from the 
same instrument for a target population in a disease state stage 
is immaterial. We cannot secure this assumption: it cannot be 
‘established by logical argument, since from the fact that all 
past futures have resembled past pasts, it does not follow that 
all future futures will resemble future pasts’ 44. Claims, for the 
relevance of a constructed imaginary world built on the 
assumption that the model elements have been validated by 
observation is simply nonsensical.  
 
Despite ICER’s continued embrace, logical positivism is dead. It 
died some 80 years ago. All knowledge is provisional. Popper’s 
contribution was to make clear that Hume’s problem with 
induction can be resolved. We cannot prove the truth of a 
theory, or justify our belief in a theory by attendant 
assumptions, since this is to attempt the logically impossible. 
We can only justify our preference for a theory by continued 
evaluation and replication of claims. Constructing imaginary 
worlds, even if the justification is that they are for ‘approximate 
information’ is, to use Bentham’s (Jeremy Bentham (1748-
1832) memorable phrase ’nonsense on stilts’. If there is a belief, 
as subscribed to by ICER, in the sure and certain hope of the 
relevance of approximate information created by imaginary 
worlds, a belief to drive formulary and pricing decisions, then it 
needs to be made clear that this is a belief that lacks scientific 
merit. 
 
Certainly, assumptions can be a critical element of models; the 
difference is the models should support testable hypotheses. 
This is echoed by Newton (Isaac Newton 1642-1727) with 
Descartes’ as his target (René Descartes 1596-1650) in saying 
‘hypotheses non fingo’ (I do not feign hypotheses).  Descartes 
in Newton’s view had ‘produced fantastic and untestable ideas, 
then assumed them to be true and used them as building blocks 
of his philosophy ‘ 45.   
Measurement: The Rasch Model 
Measurement is critical for the advance of science, through 
hypothesis testing and the discovery of new facts. Even so, the 
appearance of fundamental measurement scales is rare. The 
majority of measurement scales, if they are to meet the axioms 
for invariance and sufficiency have to be constructed, 
standardized and agreed. The 17th century, with the invention 
of science, witnessed a focus on constructing instruments to 
meet fundamental measurement standards. In many cases it 
took decades for agreement on the appropriate tools; consider 
thermometry, the invention of temperature 46 .  
                                                                                                                                                                                                                                                                                                                                                                                           
Where the object to be measured is a psychological or non-
physical construct (e.g., quality of life) the situation in the social 
sciences is more complex. It was not until the early 1960s  
that recognition of the fundamental axioms of conjoint 
simultaneous measurement provided a framework for going 
beyond the notion of simple interval and ratio scales, to 
propose a framework for detecting, if they exist, measurement 
structures in non-physical attributes with interval and possibly 
ratio properties. That is, unlike ordinal scales where only the 
order of values matters and we can say nothing about the 
difference in the values, the interval or cardinal scale is one 
where we know the order and the exact difference. Unlike the 
ordinal scale which allows only statements regarding the mode 
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or median, interval scales allow addition and subtraction. This 
permits calculation of measures of central tendency and 
dispersion (e.g., effect size). However, as the interval scale does 
not have a true zero, we cannot compute ratios (i.e., 
multiplication and division). It is only with ratio scales that we 
have a true zero. The seminal contributions are those by Luce 
and Tukey, and Rasch 47 48. 
 
The critical step is to recognize the contribution of Rasch 
Measurement Theory (RMT) to constructing outcomes 
instruments in health technology assessment 14. As noted 
below, the criteria for designating a scale as meeting the axioms 
of fundamental measurement, is to develop the instrument  
by application of Rasch model standards. Otherwise, the 
instrument will generate nothing but ordinal manifest scores.  
 
The Rasch contribution is to recognize the need, if we are to 
develop the analog to measurement in the physical science, to 
produce the data (items in a questionnaire) to fit the Rasch 
model, not in, for example Item Response Theory (IRT) to fit the 
model to the data.  As an example, for a mathematics test, a 
matrix may be defined by the ability of examination candidates 
(row elements) and the difficulty level of the various items in 
the test (column elements). Patterns of relationships between 
the cells, where each cell gives the probability of an outcome 
(Yes/No) as the difference between the difficulty of an item and 
the ability of the student can be determined by applying the 
axioms of conjoint simultaneous measurement.  
 
The Rasch model, although developed independently of Luce 
and Tukey, utilizes a modified form of the axioms of conjoint 
simultaneous measurement, to assess patterns in a matrix of 
expected response probabilities; again as a function of 
differences between ability and difficulty 17. The unidimensional 
Rasch model, a focus on a single attribute or dimension 
captured in a latent construct, rests on two ‘order’ premises: 
 
 The easier the item, the more likely it is to be affirmed; 
and 
 The more able the respondent, the more likely are 
they to affirm an item 
 
Data inputs have to fit the Rasch model 14. This is in contrast to 
classical test theory (CTT) where the model is applied to the 
data. If the data items fit the Rasch model, they are translated 
from ordinal scores to interval scores where the unit of 
measurement is the logit or logs odd unit. The Rasch model 
rejects raw scores. Rather, a log-odds transformation is applied 
to these ordinal attribute measures to create a Rasch relative 
distance or interval measurement scale. This scale avoids the 
‘clumping’ of raw scores around the middle scores and 
enhances the contrast in results for, in the case of ability, for 
those at the extreme values of the scale. The purpose of the 
Rasch model is to build a measurement tool (a list of items, 
tasks, questions) that will make a meaningful assessment of a 
latent construct. Difficulty is relative to the other items in the 
scale. Each item on a unidimensional scale should contribute 
meaningfully to the construct being evaluated. Hence the 
importance of a data matrix that relates respondents and items 
coherently, is one that is more likely to represent the construct; 
hence the importance of fit statistics in developing the item, 
respondent choice and order.   
 
As the Rasch model, as part of its development, establishes 
construct validity as well as the application of other CTT 
assessments to the items provisionally selected prior to fitting, 
and if necessary rejecting items that do not give a good fit, the 
resulting item–based instrument has good psychometric 
properties. If a scale is to provide fundamental measurement, 
this is to be established prior to the evaluation of psychometric 
properties. This points to the importance of ensuring that 
respondents are a random sample of the target patient 
population with an assumed distribution of abilities that 
matches that of the target population. Potential items for 
incision in the Rasch model are created from qualitative 
interviews with the sample.   
 
Quality of Life as a Construct 
The foundation for a Rasch model is to agree a coherent single 
attribute or construct of what is to be measured. These are not 
clinically determined health status dimensions of symptoms 
with ordinal response levels as in HRQoL measures (which are 
not constructs but a collection of clinical responses which are 
operational not conceptual). Rather the focus in QoL should be 
on a patient-centric needs fulfillment construct that was 
proposed over 20 years ago 15 16.   The application of constructs 
in science is common as they order observations. In psychology, 
to include QoL, the same objective holds. A coherent construct 
focuses on attributes of people, situations or treatments that 
are reflected in responses to scales or other observations 49 . The 
construct theory defines a variable (QoL) in terms of a model 
with a limited set of predictor variables (items). The validity of 
a construct theory reflects the extent to which it predicts 
variations in item values and person scores 16.  The litmus test is 
objective measurement: going beyond a simple ordering 
(ordinal scales) to data-based calibrations in a common 
calibration that have interval (and possibly, ratio) scale 
properties. If a QoL instrument, or other outcomes instrument, 
fits the Rasch model then the required level of calibration has 
been achieved. Otherwise, it should be discarded as the 
response or functional levels are, by definition, on an ordinal 
scale. This may reflect in each symptom item responded to by 
the patient indicating a change from one ‘level’ to another 
(response profile) or, for the more adventurous, some attempt 
to aggregate over the item level responses. The result is still a 
comparison of manifest ordinal scores.  
 
Needless to say, few PROs are developed to capture the 
unidimensional requirements of the Rasch model. Rather, we 
have a top-down approach where physicians or expert groups, 
with typically minimal patient input, decide on the symptoms 
(health dimensions) and ordinal (e.g., Likert scale) responses 
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within symptoms. The patient voice is effectively ignored. The 
axioms of fundamental measurement are ignored (or never 
considered). The primary function of the instrument is to 
provide input to the treating physician for those symptoms and 
responses judged to be of clinical interest. 
 
Assuming Interval Measurement 
The application of RMT is to ensure that the resulting 
instrument meets the axioms of fundamental measurement. 
There is no debate over this 13 14. RMT was designed and applied 
to generate unidimensional measurement for a single latent 
attribute. It is consistent with the standards for instrument 
development in the physical sciences. Claims that a generic or 
disease specific PRO has unidimensional properties can only be 
sustained if it has been developed from day one within the 
Rasch framework or if, with possible item elimination, it can be 
demonstrated to have Rasch properties. If an instrument fails 
to meet Rasch standards, then it is, by definition, an ordinal 
instrument generating manifest scores.  
 
Ordinal measures are manifest scores; they cannot be applied 
to arithmetic operations. They cannot be used to multiply 
modeled time spent in a disease state by a utility (any utility will 
do apparently) to produce a QALY score. If time spent is 
modeled at 2 years then multiplying it by an SF-5D-3L utility of 
0.5 to yield 1 QALY is complete nonsense. Just because we label 
a utility as 0.5 by the application of a preference algorithm to 
create a number line of 0 to 1 (and putting the oddities of 
negative utilities aside), does not mean that the number line 
guarantees interval properties. It is just a space for placing 
manifest adjusted scores. We have no idea of what the distance 
between manifest scores means; 0.5 to O.55 does not ‘mean’ 
the same distance as 0.65 to 0.70. The number line could 
equally well have been anchored between 110 and 200. We 
could just as well have labeled the manifest scores A, B, C and 
D. There is no true zero (which means multiplication and 
division are disallowed).  
Otherwise we have the absurd position, exemplified in  the 
latest edition of probably the most widely used textbook in 
health care  program evaluation, where it is simply assumed 
that utilities have interval properties on the 0 – 1 scale. This is 
not acceptable even as a ‘simplifying assumption’  40. 
 
Failing to apply Rasch standards has a major impact on the ICER 
business model. While previous commentaries have pointed to 
the lack of scientific merit in the creation of imaginary worlds, 
the more recent commentaries have brought fundamental 
measurement to the fore. The construction of QALYs and 
lifetime QALY estimates are a complete nonsense for one 
reason: the utility scores that they depend on fail to meet 
standards for fundamental measurement. Constrained, in the 
case of utility scores, to an arbitrary range 0 – 1 (which allows 
mythical QALYs to be created), distortion can occurs at the 
margins with bunching toward the extremes. Mathematical 
manipulations are not logically valid.  They are incompatible 
with the construction of fundamental measurement 13 .  
Attempts to apply Rasch analysis to consider the possible 
unidimensional character of utility systems do not augur well 
for blanket assumptions of interval properties. The data 
requirements are demanding because access is needed to 
individual responses. A recent study that assessed the EQ-5D-
3L and Eq-5D-5L in persons with back and neck pain in Sweden  
receiving physiotherapy in a primary care context, while finding 
goodness-of-fit evidence for unidimensionality, found little 
other evidence to meet RMT standards, including item 
selection, limited response differentiation, differential item 
functioning and differential test  functioning 50. 
 
Also of interest is an analysis undertaken some 10 years ago of 
what the authors describe as the EQ-5D VAS measure 14. This 
study combined the EQ-5D with the EQ-VAS (visual analog 
scale) to see if together they could form a valid interval scored 
measure of HRQoL in a US representative sample with the most 
prevalent chronic diseases. The VAS responses were collapsed 
to form a 9-category item. The Rasch rating scale model was 
used to calibrate the responses on the EQ-5D-3L items and the 
Rasch partial credit model for the 9-category VAS scores. The 
EQ-5D item anxiety/depression consistently showed misfit. This 
was improved with the addition of the VAS item. The findings 
suggested: (i) The EQ-5D and EQ-VAS can be combined to 
provide an overall measure of HRQoL; (ii) they might serve as a 
suitable measurement framework for deriving population 
preference weights; and (iii) important gender-specific 
reporting differences created measurement disturbances for 
the anxiety/depression item and for the anxiety and depression 
disease groups. These results were only reported as posters and 
summarized by Bond and Cox 14. No other developments can be 
found. While of interest, these results are not sufficient to 
challenge the ordinal nature of the EQ-5D-3L and EQ-5D-5L. As 
a bolt-on item, the EQ-VAS is not present in reported EQ-5D 
scores. It is unlikely that this will be followed up.   
  
The evidence for a blanket assumption that all generic utility 
systems yield, inadvertently, interval properties across all 
disease states, to meet Rasch standards is hardly compelling. 
Evidence for the other utility systems was absent (at least from 
a systematic review). A key point to note is that the Rasch 
model is disease and target patient population specific. If ICER 
wishes to assume that in a target disease state and patient 
population the chosen utility system (e.g., EQ-5D-3L) has 
interval properties than this has to be demonstrated in each 
case. This is an impossible task. Respondent data would be 
required for the target population. The analysis may suggest 
item elimination or even possible bolt-on items (e.g., VAS 
scores). Then the resulting instrument would have to be 
recalibrated for preference scores and utility algorithms applied 
to yield a score on a 0 – 1 scale. It is easier to assume interval 
scoring and hope nobody notices.   
 
Given ICER’s commitment to the EQ-5D-3L as the ‘utility 
measure’ of choice, the absence of a commitment to Rasch 
standards means that all ICER evidence reports to date are 
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based on false measurement assumptions. It is not a question 
of ICER making a ‘reasonable assumption’ (among many other 
model assumptions) but of the reference case methodology 
failing to engage with outcomes instruments that meet, by 
construction, the axioms of fundamental measurement. 
 
At risk of repetition, if an instrument does not utilize RMT in its 
construction then it is considered ordinal. Instruments that 
have relied on CTT for their development will always be ordinal. 
RMT is designed to create instruments with fundamental 
measurement properties. While this is an obvious point, it is 
critical. If our understanding of the impact of new therapies is 
to be understood then, as in the physical sciences, 
measurement is key. Non-physical attributes such as needs-
based QoL present a challenge, but one that was met some 60 
years ago. This is in obvious contrast to the construction of 
imaginary or fantasy lifetime reference case worlds which lack 
any pretense to set the stage for hypothesis testing, relying 
instead on the weak defense that they provide ‘approximate 
information’ (or disinformation) which might possibly be of 
interest to decision makers, or the more credulous, as is the 
case with CVS and ICER recommendations  51.  
Nonsense with Ordinal Utilities 
Clearly, to maintain face, ISPOR, ICER and their leaders could 
continue to argue the case for ordinal utilities as obvious 
surrogates for interval scales. The argument here is that this is 
untenable. Unless an instrument meets demonstrable Rash 
standards for unidimensionality, to reflect a single latent 
construct, it will always be ordinal. Claiming that the instrument 
was developed using CTT is insufficient.  
Once we acknowledge the absence of interval measurement 
properties for the EQ-5D-3L, due to its development neglecting 
RMT requirements (assuming that its HRQoL characteristics 
defined a meaningful construct), then QALY modeled imaginary 
claims collapse. We also have to put to one side virtually all PRO 
measures that have been promoted and applied over the past 
30 years or more using CTT. Indeed, to emphasize the point, a 
basic assumption of rating scales is that they measure a 
common underlying construct.  We have to be able to 
demonstrate unequivocally that the instrument is based only 
on a coherent single construct and meets Rasch standards for, 
unidimensionality. Put simply, the implications of meeting the 
fundamental axioms of invariance in comparisons and 
sufficiency are essential.  
In short, for those who subscribe to the technology assessment 
meme, we have to put to one side models that fail to meet the 
RMT standards. These include multi-attribute utility systems 
such as the EQ-5D, the Nottingham Health Profile, Item 
Response Theory (IRT) measures and the PROMIS system.  To 
these would be added the hundreds of HRQoL instruments and 
others claiming to capture broader concepts of QoL.  
 
 
Rasch Confirmatory Analysis 
Over the past 20 years there have been many examples where 
Rasch analysis has been used to evaluate a PRO instrument for 
potential interval properties and the creation of summary 
scores. In some cases the extent to which the original PRO 
ordinal scales fit the Rasch model has involved minimum item 
reduction. One example is the Gibbons et al report on a Rasch 
analysis of the Motor Neurone Disease (MND) Social 
Withdrawal Scale (SMS) 52. Recognizing that the original 
instrument developed with classical test theory (CTT) would 
always, by definition, be ordinal, the 24 items in the original 
were assessed for their factor structure and evaluated for 
model fit, category threshold analysis, differential item 
functioning, dimensionality and local dependency. The four 
factor solution of the original instrument was confirmed with 
Mokken scale analysis suggesting the removal of one item and 
Rasch analysis a further three. Following this, each of the four 
scales exhibited excellent Rasch model fit.  A 14-item summary 
scale was shown to fit the Rasch model after dropping one of 
the sub-scales. This provided a total measure of social 
withdrawal.  
 
Other examples include the Hospital Anxiety and Depression 
scale (HADS) in MND where Rasch analysis led to minimum item 
reduction for the two constituent scales 53; an analysis of  the 
Mini-Mental Health Adjustment to Cancer Scale (mini-MAC) 
which required more extensive item reduction 54; the minimum 
item reduction for the Depression Anxiety and Stress Scale 55; 
and, against these, a Rasch analysis of anxiety scales in 
Parkinson’s disease  where it was concluded that none of the 
currently used anxiety scales had satisfactory measurement 
properties 56. 
 
At the same time there have been a number of cases where an 
instrument has been developed de novo utilizing the Rasch 
development model. These include a number of needs-based, 
disease specific, quality of life instruments developed by Galen 
Research 57. A previous commentary detailed these instruments 
for rheumatological diseases  10.   
 
ICER and the Indefensible 
It is of passing interest to speculate on how ICER might respond 
to this commentary where the charge is, to use a well-worn 
metaphor, that the ’emperor has no clothes’. The obvious 
response is to claim that the ‘belief’ that utility number lines 
have interval properties is a ‘state of the art’ assumption or 
dogma central to the health technology assessment meme. It 
does not have to be demonstrated, we simply accept the 
‘mystery’ of the meme. To challenge it would be an affront.  Our 
belief is that much stronger if it is not challenged. As Kant 
(Immanuel Kant 1724 – 1804) wrote in the preface to the 
second edition of the Critique of Pure Reason: I have therefore 
found it necessary to deny knowledge, in order to make room 
for faith 58.  Kant was always committed to scientific knowledge, 
but knowledge limited to experience and not metaphysical 
ideas.  
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A further response might be that as ICER has opted for a 
population focus, that generic HRQoL is a common framework. 
Acceptance by agencies such as NICE supports the proposition 
that, putting concerns with interval measurement to one side, 
the construction of imaginary incremental cost-per-QALY 
worlds for pricing and formulary decisions is a useful imaginary 
creation. After all, the claims can never be challenged. Perhaps 
it is just a game. We know the rules and assumptions, even 
though they may ignore the standards of normal science, but 
we play the game. To the extent that there are rules and 
referees to manage proposals and propose the most ‘realistic’ 
construction of future worlds where ordinal scales become 
interval, we endeavor to persevere and transmit our meme to 
future generations.  
 
The value that individuals might attach to change in health 
status is ignored. ICER would put these concerns to one side and 
argue that the ‘state of the art’ in modeling imaginary worlds 
demands population preferences or weights to drive ordinal 
utility scores, create QALYs, and propose meaningless 
measures of incremental ‘change’. If we are to introduce some 
consideration for the ‘patient voice’, meeting the needs of 
patients, then this is seen by ICER as an afterthought. Certainly 
concerns might be raised, such as the scope of the health 
dimensions, the relevance of response level sensitivity, the 
input from caregivers and issues such as access to care, but 
these are secondary to the central role of community 
preferences in driving clinically focused therapy response 
captured in a handful of ordinal health manifest scores to 
generate nonsensical QALY estimates and pricing 
recommendations.  
 
ICERs insistence on its multi-attribute generic utility score to 
support its imaginary QALY claims means that it sees no role for 
disease specific measures that meet RMT criteria in assessing 
competing products.  ICER’s contribution is to trawl the 
literature for likely ordinal utility candidates to populate its 
modeled imaginary worlds. ICER has no intention of discovering 
new facts; it has no commitment to the contribution of normal 
science, rather it is concerned to provide ‘approximate 
information’ that fails the requirements of fundamental 
measurement.  
 
ICER might insist on a ‘population’ perspective for the imaginary 
VAF model arguing that: Taking a population perspective 
implies that the ICER value framework seeks to analyze evidence 
in a way that supports population-level decisions and policies, 
such as broad guidelines on appropriate care, pricing, insurance 
coverage determination, and payment mechanisms. Again 
while these are no doubt commendable objectives in health 
care planning the population focus suffers from two limitations: 
(i) the value metrics that are presumably intended to support 
policies and guidelines fail the standards for fundamental 
measurement; and (ii) the insistence on clinically operational 
symptoms and responses rather than measures which are 
patient centric and which, again, fail the required measurement 
standards. Happily, though, the ICER model VAF creates an 
explicit place and role for consideration of elements of value 
that are important to individual patients but that fall outside 
traditional clinical measures.  
 
It would have been more useful for ICER to recognize, not only 
the constraints of ordinal measurement, but that we have the 
Rasch model for taking explicit account of patient needs with 
RMT standard instruments available across a range of disease 
areas. Abandoning a population focus and ordinal utilities 
would open the doors for ICER to focus on the assessment of 
new and competing therapies, to discover new facts, with 
models designed to generate credible claims. Not only would 
the instruments have interval properties, but their potential 
focus on a needs-fulfilment QoL construct would put functional 
status to one side in favor of the patient voice.  
 
Which QALY Metric? 
If the embrace of the health technology assessment meme is to 
embrace an indefensible standard, then the ICER business 
model collapses. However, for the purpose of argument, if we 
put the lack of scientific merit to one side, then there are issues 
which ICER has yet to address if it persists in its dogged belief in 
imaginary ordinal worlds. A major concern must be the 
indiscriminate use of the term ‘QALY’ in the ICER evidence 
reports. The impression is given, perhaps inadvertently, that 
there is some objective ordinal QALY ‘gold standard metric’. 
Unfortunately, different utility metrics and different models 
will create different QALYs even for the same target population 
and therapy comparisons. What ICER appears to have 
overlooked is that the various generic ordinal utility scales are 
different. As Drummond et al point out, there is no simple 
answer to the question of which preference based multi-
attribute health status system to use, or whether to opt out : (i) 
the decision does matter as the systems are far from identical, 
they differ in the health dimensions and levels assigned to each 
dimension, in the description of those levels and in the severity 
of the most severe level; (ii) they differ in the population 
surveyed in the construction of the system and the instruments 
used to determine the preference based scoring; and (iii) they 
differ in the theoretical approach taken to modeling the 
preference data into a scoring formula 59.  Even so, the issue of 
fundamental measurement is not raised. 
 
Although a review of previous ICER evidence reports might have 
suggested that ICER has, in practice, adopted the EQ-5D-3L 
system as the preferred ordinal metric,  this is put to one side if 
a literature review is not successful in locating the preferred 
metric for target patient populations. In this event ICER has on 
occasion brought in another utility metric. This is seen in the 
ICER modeling of oral semaglutide for Type 2 Diabetes (T2DM) 
where it is stated: The utility values for events modeled from the 
risk equations were drawn from two sources due to a lack of a 
single comprehensive source of health-related quality of life 
inputs. It is also important to point out that the two sources 
used different preference-weighted measures (EQ-5D and 
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HUI3), and these two instruments are known to produce slightly 
different utility estimates (emphasis added) 60. Not only is the 
case for cardinal measurement overlooked, but for ICER the 
choice of utility metric appears to be incidental to capturing any 
utility assumptions for modeling. 
For an organization which sees itself in pole position for 
excellence in reference case health technology assessment 
modeling in the US, as the arbiter for ‘state of the art’ standards 
in the modeling of imaginary worlds, this is a most unfortunate 
statement. There are no references given for this claim, 
specifically for references supporting this claim for the target 
T2DM target population which ICER is attempting to model. 
Indeed, if ICER is to make unsupported claims for ordinal utility 
‘equivalence’ (i.e., they may be different constructs but we 
assume they are pretty much the same) then it should have 
provided a systematic review of ordinal utility metrics in the 
target T2DM population. Only then, for those who believe in 
the construction of imaginary worlds, could this assumption 
have been justified. If ICER is to provide justification for its 
utility choice then ICER should apply the review standards 
proposed by the ISPOR SPRUCE checklist (Minimum Reporting 
Standards of Systematic Review of Utilities for Cost-
Effectiveness Models) 61. These standards might, in retrospect, 
be re-labelled to include the term ‘ordinal’. 
 It is also of interest to note that, for those trawling the 
literature for ordinal utilities to populate imaginary worlds 
there is what might be described as an ‘ordinal’ utility 
emporium, the Tufts University Cost-effectiveness Analysis 
(CEA) Registry, which since 1976 has assembled a database of 
over 8,000 cost-utility analyses 62. Apparently, for those utility 
models selected for inclusion some 40 data points are 
extracted. These include utility values and cost-per-QALY 
claims. There does not seem, however any check on whether 
the utility scales meet the required axioms of fundamental 
measurement. While one would hesitate to describe this 
confection of cost-per-QALY studies as a redundant 
undertaking, this assemblage would surely rank alongside the 
relic collection of Federick III, Elector of Saxony (1463-1525)63. 
A further issue which deserves attention is the application of 
mapping to generate ordinal utility metrics from clinical 
markers. It is unusual to find protocols for Phase 3 clinical trials 
mandating the use of a multi-attribute utility instrument as an 
endpoint (either primary or secondary). As a result, as the ICER 
reference case notes, a utility metric can be created from a 
selected clinical marker. There is an extensive literature for this 
as the incentive, at least outside of the US, is to respond to 
guidelines by NICE and others to populate their ordinal 
reference case models with a generic multi-attribute metric for 
formulary submission. As a result considerable effort has gone 
into developing mapping algorithms to populate imaginary 
constructs. Putting questions of fundamental measurement to 
one side, two issues are important: (i) the choice of mapping 
algorithm and (ii) the choice of clinical marker. As to the latter 
point, there may be a number of relevant clinical markers that 
may capture the stage of disease and the response to therapy. 
There has to be justification for the one that is used. As a result 
objections may be raised that this is not the most relevant, even 
though the ‘ordinal’ exercise is pointless.  
Unfortunately, ICER provides no guidance as to the choice of 
indirect or mapped ordinal utility metric? Are the mapping 
algorithms relevant to the target reference case hypothetical 
population? Given these uncertainties, it would be appropriate 
for ICER, not only to report, as noted above, on the utility 
metrics reported in the literature for the target disease state 
and population, but to provide a detailed justification for the 
choice of mapping function and metric. In this respect ICER 
should follow the ISPOR good practice guidelines for mapping 
from non-preference based outcomes measures 64. This, once 
again, may be of academic interest yet from a practice 
perspective is pointless. 
A Multiverse of Imaginary Worlds 
If we accept the belief that the central role of health technology 
assessment is to construct ‘approximate information’ ordinal 
imaginary worlds, then it is reasonable to point out that there 
is a potential multiverse of imaginary ordinal worlds generating 
a potential tsunami of conflicting ordinal and illogical cost-per-
QALY claims. While it might not be clear as to whose value 
(physician, patient, insurer, health system) a model is 
considered to represent, the model builder can press forward 
in the sure and certain hope that the claims made will escape 
any scrutiny. The claims are ‘for approximate information only’ 
and are not intended, as detailed above, to meet standards for 
empirical credibility, evaluation and replication in treating 
environments. Claims will not be deconstructed; they will be 
taken at face value. After all, considerations of the axioms of 
fundamental measurement are unlikely to resonate with 
formulary committee members and even media 
representatives. 
Choose your Disease Stage 
Assuming that our belief in the ICER reference case is not yet 
completely undermined, there is a further issue to consider: the 
structure of the modeled imaginary world.  The model structure 
will determine the time spent by the hypothetical patient 
population in each disease stage as their assumed lifetime 
experience of the disease unrolls. Different model structures 
and assumptions regarding transition probabilities between 
modeled disease states will provide different estimates of time 
spent. This may be further augmented by assumptions as to 
significant adverse events within disease stages and the 
corrections made to capture their impact on the ordinal utility 
score (not possible with ordinal manifest scores). Clearly, with 
the range of model frameworks to choose from, ICER should be 
in a position to justify its decision on the number of disease 
states, the time spent in each state and the basis for the 
transition probabilities compared to other models in the 
literature. 
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Choose your Costs 
The final element in the construction of an imaginary 
incremental ordinal cost-per-QALY claim is the composition of 
the numerator: how has ICER defined the direct medical costs 
to populate the model over its hypothetical distant lifetime? 
Should the base case costs reflect assumed societal costs as the 
EQ-5D represents societal preference? Are there cost elements 
that have been put to one side? What assumptions have been 
made regarding how costs may increase over time? Obviously 
there is considerable flexibility which will impact the cost claims 
(which, of course, are discounted) and any threshold criteria in 
the potential multiverse of imaginary social engineering 
models.  
Choose your Thresholds 
There is an ongoing debate in the technology assessment 
literature over the past decade on the relevance of willingness 
to pay, cost-per QALY thresholds. Cleemput et al, writing in 
2011, take the view that incremental cost-effectiveness ratios 
(ICERs) and ICER threshold values are insufficient for assessing 
interventions’ value for money and should be considered as 
only one element in the decision making process, although the 
weight that might be placed on them is unclear  65. Since then, 
a vague consensus has emerged that recommends that a mix of 
factors should accompany any threshold recommendations in 
formulary decisions. Recommendations, it should be noted, 
that are redundant once we accept the impossibility of 
constructing lifetime cost-per-QALY claims with interval 
properties to match to thresholds. A cost-per-QALY threshold 
value itself has no meaning as a ‘cost’ cannot be ‘attached’ to a 
manifest ordinal utility score creating QALYs. Again, thresholds 
assume interval utility properties. 
A smorgasbord of value frameworks has been proposed, none 
of which has received more than ‘local’ approval by a 
professional group or consultants proposing a marketable 
package. ICER has proposed in its VAF that it will explore the 
possibility of quantifying ‘broader’ measures of value, 
postponing any decision until some consensus is achieved 
between ICER, stakeholders and other parties (i.e., in the 
fullness of time or never). Barring such a communion, the 
threshold based ordinal imaginary recommendations will 
continue to take center stage. This has led commentators to 
suggest that the various thresholds should be built into early 
modeling of the feasibility of a compound achieving an 
acceptable ‘judgment’ for cost-effectiveness. This is nonsense; 
after all, which model do we choose? 
The 2020 ICER VAF continues to utilize in reporting on its 
imaginary worlds a standardized set of cost-effectiveness or 
willingness to pay thresholds ranging from $50,000 to $200,000 
per imaginary yet logically invalid  QALY ‘count’. The dollar 
threshold is an arbitrarily assumed amount that the US 
community (i.e., health systems) might be willing to pay for 
additional QALYS across all disease states. The ‘value’ of a 
product is the relationship between the nonsensical 
incremental cost-per-QALY claim and the various hypothetical 
thresholds.  
 
For value based pricing benchmarks ICER will continue to use 
the range $100,000 to $150,000 per QALY. In maintaining a 
common set of thresholds, the impression is given, presumably 
mistakenly, that these standardized thresholds will yield 
comparable estimates for price discounting and affordability 
across model options including choice of utility metric. As noted 
above, an imaginary cost-per-QALY claim will depend on 
assumptions regarding: (i) the ordinal utility metric assigned to 
disease stages; (ii) the number and duration of disease stages 
and (iii) the assumed direct medical costs for each disease 
stage. If a $100,000 threshold, applied to a specific model 
yields, for example, a recommended 25% price discount, a 
model that differs in any one or a combination of these 
assumptions will yield a different discount recommendation. 
The threshold, in other words, is specific to the model structure 
and assumptions. 
 
The conclusion must be, given the vagaries of the ICER 
reference case, that thresholds are misleading (and redundant).  
They represent a construct based on a lifetime imaginary world 
that lacks scientific merit. There is a nagging feeling that what 
has occupied analysts in health technology assessment for over 
30 years has no social value.  One is reminded of Wilde’s (Oscar 
Wilde 1854 – 1900) observation on fox hunting: the 
indescribable in pursuit of the inedible.  
 
Needs and the Patient Voice 
If health technology assessments are to become more than the 
construction of HRQoL imaginary worlds to support threshold 
claims, specific to the reference model, and which fail to meet 
the standards of normal science, then we have to consider 
alternative outcome frameworks. Central to any meaningful 
assessment framework is the patient voice in therapy response. 
This is not easily achieved. ICER’s embrace of generic multi-
attribute ordinal measures, even if it involves employing 
different HRQoL measures in the same model, ignores the QoL 
of patients in that disease state.  
 
It is important to make the point that the majority of HRQoL 
measures were not intended, nor designed to determine the 
value to patients of alternative health states, both generic and 
disease specific. A necessary starting point is to make a 
distinction between patient reported outcome (PRO) measures 
and patient-centric outcome (PCO) measures 66 49. PROs 
encompass a range of outcomes, including clinical status, 
treatment satisfaction, quality of life and utility.  One PRO 
definition, focusing on HRQoL, narrows the scope to how 
respondents feel and function: ‘how they feel or function in 
relation to a health condition’ 49. This, from the patient’s 
perspective may be irrelevant, failing to take account of other 
factors that may impact QoL in the lives of patients such as 
access to care, financial resources, education, caregiver support 
and even the personality of the patient.  
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PCOs are, by definition, disease specific; patients’ needs can 
only be evaluated with reference to their disease state (or a 
combination of states if comorbidities are present) 49. The 
needs of patients, where rare diseases which impact the 
patient, caregiver and wider family are a case on point, can only 
be understood from the patient’s perspective. The underlying 
needs-based construct focuses not on the measurement of 
symptoms and activity limitations (HRQoL) but on the impact of 
therapy interventions on the lives and needs of the patient 49.  
 
Patient centric, disease specific, outcomes instruments start 
from a needs-based construct. The needs model hypothesizes 
that the value of individual lives is dependent on the extent to 
which their human needs are fulfilled. Value is low when few 
needs are met 49 . The major factors in needs fulfillment are the 
presence and treatment of disease. Clinical HRQoL ordinal 
manifest scores for the symptoms covered may ‘improve’ 
through treatment, without necessarily impacting patient 
value. The numerical value of any improvement (change in 
response level) is, of course, unknown. 
 
The starting point for a needs-based instrument is in-depth 
interviews with patients 49. These identify common issues and 
are the basis for creating an item set for application to the 
Rasch model. The objective is to create a unidimensional 
interval scale to capture the latent needs construct. The 
measure is an index that determines the extent to which needs 
are met and the impact of therapy options. PCOs are a direct 
reflection of the patient voice; there is no need for an artificial 
distinction between EQ-5D ordinal utilities to drive 
(unacceptable) population health focused value claims and 
‘issues of interest to patients’. If there are clinical attributes 
that are important in a disease state then these will be captured 
in the PCO.  
 
Exeunt Ordinal QALYs 
If the only reason for focusing on ordinal QALY scores, with the 
assumption that they have interval and even ratio properties, is 
to justify the role of imaginary worlds in value assessment, then 
we might well ask why? Is it because, with a perceived need to 
make an upfront value assessment of a product, we can put the 
standards of normal science to one side and convince a, 
possibly ill-informed audience, that this is the gold standard? Is 
this the only way that ICER can demonstrate the worth of its 
reference case?  
 
To assume, without any justification, that any utility score 
created by a system such as the EQ-5D-3L on a zero to unity 
number line must have interval scoring properties for any 
target patient group of interest is absurd. These various generic 
systems (SF-6D, HUI Mk3, etc.) were not designed to meet RMT 
standards. They are a selection of symptoms with ordinal 
responses.  
 
On the other hand we could admit that the incremental 
population-focused incremental cost per QALY reference case 
is an analytical dead end. ICER may claim that their model is the 
‘one to watch’ or, rather, avoid. If so, it hardly gives decision 
makers a justifiable evidence base.  Formulary decisions should 
not be based on ‘approximate information’ for QALYs over the 
next 30 years driven by dubious assumptions. In a previous 
commentary, following a review of the practical impact of 
modeled cost-per-QALY claims it was concluded that: In 
retrospect, it is doubtful, that the great expectations for QALYs 
could ever be realized outside of reference case imaginary 
worlds, or the willingness of decision makers to suspend belief 
in the standards of normal science, and accept lifetime cost-per-
QALY claims as decision criteria. Unless, therefore, a case can be 
made for short-term and evaluable QALY claims, there seems 
little scope for QALYS, and associated cost-per-QALY claims, as 
inputs to formulary decision making. Perhaps, as Pip says to 
Estella, it has been ‘a vain hope and an idle pursuit’ 67. After over 
30 years perhaps we can put QALYs to one side and return to 
clinically and quality specific endpoints  in comparative claims 
for pharmaceutical products in disease and therapeutic areas 68. 
 
Value Claims: Meeting Acceptable Evidence Standards 
The last few years have seen a number of organizations propose 
value claim frameworks for evaluating products. Unlike the 
one-size-fits all ICER reference case, these frameworks are 
disease specific. Most recently, the National Pharmaceutical 
Council (NPC) has released recommendations for value 
assessment frameworks 69. Putting to one side the question of 
who is going to implement these recommendations, sections 
on (I) methodology and (ii) benefits are of interest as they point, 
in implicitly accepting the technology assessment meme,  to the 
failure to recognize the importance of meeting the standards of 
normal science in the application of ‘established’ health 
economic methodologies and the claims made. For the NPC 
‘methods should be based on established health economic 
methodologies, consistent with established standards’. 
Following these standards, continue the NPC, is necessary ‘to 
produce a meaningful and credible assessment of value’. While 
not mentioning the role of reference case guidelines, NPC is 
clearly in support of the creation of ordinal imaginary worlds 
and pseudoscientific opinions; claims that fail the demarcation 
test. Whether they recognize this is an open question.  
Presumably the term ‘credible’ in the case of the imaginary 
centerpiece is not meant to be interpreted as amenable to 
empirical assessment (e.g., hypothesis testing of a value claim).  
 
More to the point, the NPC continues, base case assumptions 
(presumably the ICER reference case) ‘must represent reality’; 
they must be ‘realistic and accurate.’  It is unclear how NPC 
would judge assumed claims for ‘realty’, ‘realistic’ or ‘accurate’. 
The question of whether or not assumptions regarding 
imaginary worlds 10, 20 or 30 years into the future, the ICER 
reference case, can ever be supported as ‘realistic’ is absurd. 
Although the NPC seems willing to accept that ICER can 
represent reality 30 years ahead, even going a few years ahead 
raise the same objections, let alone an agreement even now 
that a model assumption’ is realistic’. After all we do not judge 
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models on the realism of the assumptions (Hume’s induction 
problem). The NPC recognizes that different assumptions will 
yield different outcomes, or more accurately, different 
imaginary outcomes. But if there are different assumptions, 
how do we determine which assumption is ‘more realistic’ than 
another? 
 
NPC then goes on to recommend that weights should be 
included in any assessment to reflect different user 
preferences, although how this is to be achieved or how the 
weights are to be assigned to the various health dimensions and 
preferences is unclear. Is the NPC suggesting we bundle the 
various piece or imaginary and other evidence into a multiple 
criteria decision framework? The limitations of multiple criteria 
decision analysis (MCDA) are well known70.   Are we proposing, 
for example, to redistribute multi-attribute weights and create 
new ordinal utility scoring algorithms from preference scoring 
by different target groups? Users should be allowed, 
presumably within this imaginary construct, to adjust 
assumptions and parameters to accommodate individual 
preferences for different outcomes and factors, and make 
adjustments to represent different scenarios. A wealth or 
imaginary ordinal constructs. Presumably, formulary 
committees will be presented with these numerous imaginary 
worlds tailored to the needs of different patient and payer 
interests, whether expressed as incremental generic cost-per 
QALY or some other PRO construct, presented as meeting their 
interpretation of the standards of health technology 
assessment in constructing multiple imaginary worlds for target 
disease states. As Lear remarks to Kent, reflecting on Goneril 
and Reagan’s filial ingratitude: ‘O, that way madness lies; Let 
me shun that’71. Or, in more prosaic terms, if there are credible 
NPC recommendations then it needs to be clearly stated as to 
how these are to be implemented. 
 
Rather than putting to one side lifetime model standards, 
tailored to the preferences of the interested parties, the NPC 
accepts the reference case lifetime perspective to support 
imaginary claims: The time horizon for value should be long 
term, ideally lifetime …. Many of the benefits …. Show up in the 
longer term …. The time horizon (to capture these) …. Should be 
long enough to capture those benefits, ideally covering a 
patient’s lifetime. As detailed in this commentary, this is 
pseudoscience; there is no apparent appreciation by the NPC of 
the role of discovery, of the requirement for claims to be 
credible, evaluable and replicable. The question of scientific 
method has not even surfaced, let alone fundamental 
measurement and RMT. Certainly, different models that 
generate credible and evaluable claims can be proposed. The 
key point is that these models should be judged on their 
empirical merits; on the assessment of their claims. Not on the 
realism or otherwise of their preferred assumptions. Perhaps 
the NPC might reconsider its support for imaginary reference 
case worlds.  
 
 
Conclusions:  ICER - The Unnecessary Distraction 
Media releases following the release of ICER reports focus on 
the recommendations made for pricing and affordability. 
Health system decision makers are asked to take the ICER 
recommendations ‘at face value’. There seems little debate 
over the lack of scientific merit in constructing ICER imaginary 
worlds. Any notion of fundamental measurement to drive 
claims is a foreign country. 
 
Health care decision makers deserve better. Rather than 
continually applying model standards for imaginary constructs 
that do nothing to uncover new facts, groups such as ICER (and 
the supporting university-based consultants) would be better 
advised to reconsider their role in providing support for 
evidence-based formulary decisions. This may not be as 
appealing as creating fantasy scenarios and basking in the 
resulting media attention, but at least it would give ICER some 
claim to meeting the demarcation test.  
 
If our standard is that claims made for therapy outcomes should 
pass the demarcation test, then the patient-centric approach is 
on firm ground.  Rather than reflecting the interests of 
professionals, clinicians and even expert panels, it is grounded 
in the view that QoL therapy assessments should be needs-
based and disease specific. Instrument development has to 
meet RMT standards. 
 
Given the arguments presented here against the ICER reference 
case, it is clear that from the standards of normal science the 
ICER evidence reports are, from the modeling perspective, a 
waste of time. Failing to meet fundamental measurement 
standards means that ICER must repudiate all previous 
evidence reports. Whether manufacturers and other 
‘stakeholders’ should continue to engage in this charade has an 
obvious answer.  
 
Most importantly, given the apparent lack of appreciation of its 
manifest failures, ICER is an unnecessary distraction. 
Manufacturers and patient interest groups have to divert 
resources to relay their concerns over the ICER clinical claims as 
well as modeled claims. Unfortunately, given the perceived 
complexities in reference case modeling, manufacturers, health 
system decision makers and insurers take the ICER claims at 
face value. This cannot continue, but probably will as there is 
too much vested in the ICER imaginary world business model.  
  
The purpose of this commentary has been to point to the 
manifest flaws in the ICER VAF approach. Rather than talking 
about more complex value assessment frameworks, the 
introduction of qualitative consideration and even multi-
criteria decision analysis (MCDA), we should step back and ask 
the fundamental question: if we accept the relevance of the 
scientific revolution of the 17th century, the invention of 
science, then we should require that claims for comparative 
effectiveness to be credible, evaluable and replicable. 
Continuing to take notice of ICER modeled claims, which are 
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best seen as the analog of intelligent design seems pointless. 
Memes certainly have a life of their own, but there is no reason 
why we can’t reject them (a memetic reformation). One reason 
ICER and ISPOR talk about the ‘need’ to bring in, on an ad hoc 
basis, ‘considerations’ that are relevant to patients and 
caregivers is that the reference case model fails to capture 
these in the first place. Preference based, multi-attribute 
preference instruments are irrelevant; we need PCOs not PROs.  
 
We will also have to reconsider the role of QALYs. They have 
been subject to considerable criticism apart from their 
unacceptable measurement properties 72. Taken together with 
their reliance on ordinal utility scores, the case can be made 
that it is pointless to continue to argue for generic cost-per-
QALY constructs. QALYs should be abandoned. There is no 
evidence that the EQ-5D-3L or other utility systems have 
interval scoring properties. To assume that is absurd. 
 
Utilities must be put to one side. With the focus on disease 
specific PCO scores as our outcome measure, translating these 
into utilities, which is possible, seems unnecessary 73. The lost 
opportunity in abandoning the HRQoL meme is made the more 
pointed by the fact that these arguments were made some 15 
years ago in the ISPOR house journal Value in Health 15 16 17. The 
fact that they had to be repeated some 15 years later in the 
Journal of Medical Economics merely reinforces the point that 
the HRQoL meme is well entrenched in technology assessment 
belief systems 18 19 49. Awkward issues of meeting RMT 
standards for instrument development can be thankfully put to 
one side; after all, truth is consensus. 
 
Formulary decisions can equally well be based on disease 
specific evaluable cost-per-PCO claims in a time frame that 
allows these to be evaluated and reported back to formulary 
committees, not in a ridiculous imaginary lifetime framework. 
This point was made some 15 years ago in developing draft 
guidelines for WellPoint (now Anthem) and in the proposed 
Minnesota formulary guidelines released in 2016 74 75. If there 
is a PCO with overlapping items for each disease state, then we 
have a metric that can be used to support ongoing therapy 
assessments and provide comparisons between therapies in 
different disease states 76.   If this is accepted, then we put to 
one side many of the hundreds of PROs that have emerged over 
the past 30 years; many of them developed to support just one 
or two studies. If the patient voice is to resonate in formulary 
decision making, then it can be through the development of 
psychometrically sound, RMT based, PCO instruments.   
 
In summary, if we are concerned with the discovery of ‘new 
facts’, even though these are necessarily provisional, then the 
ICER reference case modeling of imaginary worlds is an 
intellectual and analytical dead end. ICER is clinging to a meme 
that has been a distraction for 30 years. More to the point, it is 
an unnecessary distraction. It is based on the assumption that 
ordinal utility manifest scores have interval properties. They do 
not. They were never intended to have interval properties 
because those developing the various scales had no conception 
of the potential contribution of RMT. This is an oversight that 
should not have happened. There was ample evidence for the 
application, at the time of their development, of RMT to ensure 
interval properties. 
 
This arguments presented here will no doubt be challenged. 
After all, memes have considerable staying power. Mysteries 
reinforce this; perhaps we should call the accepted 
‘transformation’ of ordinal to interval scales a mystery. As 
Dawkins notes faith can be strong despite not being based upon 
evidence 39. Solving mysteries can be inimical to ‘the spread of 
a mind virus’ and perhaps ‘it is not a virtue to solve mysteries’. 
  
 
If ICER wishes to persevere in this Homeric odyssey through 
imaginary worlds then, to extend the metaphor, before 
embarkation, it will need to demonstrate that the proposed 
utility system has interval scaling properties for the target 
patient population in the disease group. This would save on                                          
time and effort in building modeled cost-per-QALY claims which 
were then rejected by decision makers on fundamental 
measurement grounds. 
 
The question we should ask is: If ICER ceased to exist, would it 
be missed? If the standards of normal science are applied, the 
answer is ‘no’. Constructing a base case imaginary reference 
standards world, where the modeled claims are only one of a 
possible multiverse of competing claims, allied to a threshold 
willingness to pay recommendation for pricing that is specific to 
the assumptions driving the model, is nonsense on stilts.    
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